Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival
Clinical Medicine & ResearchPublished 1 June 2009Open access
A. A. Onitilo, J. M. Engel, Robert T. Greenlee, Bickol N. Mukesh
Citations844
SJR quartileQ2
SJR score0.36
SNIP0.53
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
The triple negative subtype has the worst overall and disease free survival. Efforts should be directed at standardization of current testing methods and development of more reliable and reproducible testing.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
New England Journal of MedicineA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
6,520 Citations2002Marc J. van de Vijver, Yudong D. He +19 more
The gene-expression profile studied is a more powerful predictor of the outcome of disease in young patients with breast cancer than standard systems based on clinical and histologic criteria.
New England Journal of MedicineA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
6,253 Citations2004Soonmyung Paik, Steven Shak +13 more
The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.
Proceedings of the National Academy of SciencesRepeated observation of breast tumor subtypes in independent gene expression data sets
5,411 Citations2003Thérese Sørlie, Robert Tibshirani +14 more
The results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities.
New England Journal of MedicineTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
5,353 Citations2005Edward H. Romond, Edith A. Perez +23 more
Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Clinical Cancer ResearchTriple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
5,106 Citations2007Rebecca Dent, Maureen Trudeau +8 more
Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.
New England Journal of MedicineTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
5,098 Citations2005Martine Piccart, Marion Procter +30 more
One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal of Clinical OncologyAmerican Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
4,475 Citations2006Antonio C. Wolff, M. Elizabeth H. Hammond +21 more
A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
JAMARace, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
3,834 Citations2006Lisa A. Carey, Charles M. Perou +15 more
Basal-like breast tumors occurred at a higher prevalence among premenopausal African American patients compared with postmenopausal American and non-African American patients in this population-based study, and their associations with tumor size, axillary nodal status, mitotic index, nuclear pleomorphism, combined grade, p53 mutation status, and breast cancer-specific survival were examined.
The LancetGene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2,687 Citations2005Yixin Wang, Jan G.M. Klijn +12 more
The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options.
The LancetResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
2,281 Citations2005Anthony Howell, Jack Cuzick +8 more
Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer, especially gynaecological problems and vascular events, but arthralgia and fractures were increased.
Clinical Cancer ResearchThe Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
2,118 Citations2007Lisa A. Carey, Elizabeth Claire Dees +8 more
Basal-like and HER2+/ER− subtypes are more sensitive to anthracycline-based neoadjuvant chemotherapy than luminal breast cancers and could be explained by a higher likelihood of relapse in patients in whom pathologic complete response was not achieved.
Archives of Pathology & Laboratory MedicineAmerican Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
1,852 Citations2007Antonio C. Wolff, M. Elizabeth H. Hammond +21 more
A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
New England Journal of MedicineConcordance among Gene-Expression–Based Predictors for Breast Cancer
1,342 Citations2006Cheng Fan, Daniel Oh +6 more
Four of the five gene sets used for prognostication in patients with breast cancer showed significant agreement in the outcome predictions for individual patients and are probably tracking a common set of biologic phenotypes.
The LancetGene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
1,227 Citations2005Yongyu Wang, J.G.M. Klijn +8 more
Proceedings of the National Academy of SciencesRobustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
997 Citations2005Howard Y. Chang, Dimitry S.A. Nuyten +11 more
New England Journal of MedicineThe Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells
986 Citations2007Rui Liu, Xinhao Wang +8 more
The gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium was compared to generate a 186-gene "invasiveness" gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer.
New England Journal of MedicineThe Decrease in Breast-Cancer Incidence in 2003 in the United States
977 Citations2007Peter M. Ravdin, Kathleen A. Cronin +6 more
An initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries shows that the age-adjusted incidence rate of breast cancer in women in the United States fell sharply in 2003, as compared with the rate in 2002.
Journal of Clinical OncologyFive Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
904 Citations2007Alan S. Coates, Aparna Keshaviah +18 more
The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.
Journal of Clinical OncologyBreast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
819 Citations2008Paul L. Nguyen, Alphonse G. Taghian +8 more
Overall, the 5-year local recurrence rate after BCT was low, but varied by subtype as approximated using ER, PR, and HER-2 status, which may be useful in counseling patients about their anticipated outcome after B CT.
New England Journal of MedicineHER2 and Response to Paclitaxel in Node-Positive Breast Cancer
604 Citations2007Daniel F. Hayes, Ann D. Thor +14 more
The expression or amplification, or both, of HER2 by a breast cancer is associated with a benefit from the addition of paclitaxel after adjuvant treatment with doxorubicin plus cyclophosphamide in node-positive breast cancer, regardless of estrogen-receptor status.
Cancer ResearchPhase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
554 Citations2009DJ Slamon, W. Eiermann +20 more
The results of this trial help define the role of trastuzumab in the breast cancer HER2-positive adjuvant setting, as well as the risks/benefits of adjUvant trastzumab within the context of overall safety including cardiac toxicity.
JNCI Journal of the National Cancer InstituteBreast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status
437 Citations2007Andrew G. Glass, James V. Lacey +2 more
From 1980 through 2006, quantitative and qualitative trends in breast cancer incidence rates, particularly for ER+ tumors, parallel major changes in patterns of mammography screening and use of menopausal hormone therapy.
JNCI Journal of the National Cancer InstituteConcordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831
402 Citations2002Patrick C. Roche, VJ Suman +8 more
The poor concordance between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831, a prospective, randomized, three-arm, phase III trial for women with primary, operable, histologically confirmed, node-positive breast carcinoma.
Journal of Clinical PathologyReliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems
332 Citations2000Anthony Rhodes, Bharat Jasani +3 more
There is considerable interlaboratory variability, especially in relation to the detection of breast cancers with low oestrogen receptor positivity, with a false negative rate of between 30% and 60%.
American Journal of Clinical PathologyMinimum Formalin Fixation Time for Consistent Estrogen Receptor Immunohistochemical Staining of Invasive Breast Carcinoma
280 Citations2003Neal S. Goldstein, Monica Ferkowicz +3 more
The minimum formalin fixation time for reliable immunohistochemical ER results is 6 to 8 hours in the authors' laboratory, regardless of the type or size of specimen.
Breast Diseases A Year Book Quarterly1–1 Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
168 Citations2007Lisa Carey, Charles Perou +153 more
Molecular Cancer TherapeuticsGene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
127 Citations2006Thérese Sørlie, Charles M. Perou +9 more
A statistical analysis of large-scale gene expression patterns and their relationship to response following neoadjuvant chemotherapy in locally advanced breast cancers could not uncover a gene profile that could reliably predict response to either treatment regimen.
Clinical Cancer ResearchClassification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
109 Citations2006Marisa Dolled‐Filhart, Lisa Rydén +5 more
This work illustrates the potential for multiplexed biomarker discovery on the tissue microarray platform and has both the familiarity and specificity for widespread use in management of breast cancer.
The American Journal of Surgical PathologyQuality Assurance in Immunohistochemistry
102 Citations2002Thomas Rüdiger, Heinz Höfler +9 more
The major problem of applying immunohistochemistry in surgical pathology appears to be its integration into the diagnostic process and not the staining quality, and both future quality control projects and training will have to regard these integrative requirements.
Obstetrical & Gynecological SurveyResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 Years??? Adjuvant Treatment for Breast Cancer
70 Citations2005
American Journal of Clinical PathologyMinimum Formalin Fixation Time for Consistent Estrogen Receptor Immunohistochemical Staining of Invasive Breast Carcinoma
60 Citations2003Neal S. Goldstein, Monica Ferkowicz +3 more
Breast Cancer Research and TreatmentShort-term outcome of primary operated early breast cancer by hormone and HER-2 receptors
28 Citations2008Olivier Brouckaert, S Pintens +19 more
The short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype is reported, confirming the prognostic value of currently used IHC markers for ER, PR, and HER-2.
PathologyEvaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome
24 Citations2006Glenn Francis, Geoffrey Beadle +3 more
Oestrogen receptor status cannot be used to select tumours for evaluation of HER‐2 status, and oestrogen and progesterone receptor positivity does not preclude a positive HER‐1 status, but there is a higher proportion of ERp negative tumours associated with Her‐2 positivity, however, more than 20% of HER-2 positive tumours show moderate or strong staining for ERp.